The modern landscape of neurodegenerative therapeutics is defined by an urgent quest for disease-modifying interventions capable of altering the destructive trajectory of progressive motor disorders. Among these conditions, Parkinson’s disease stands out as a complex pathology driven by the selective degeneration and loss of dopamine-producing neurons within the substantia nigra pars compacta, leading to debilitating […]